Evaluation of the effect of dimenhydrinate on Benign Paroxysmal Positional Vertigo after maneuver therapy of Epley

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT138905032893N2

Enrollment

148

Registered

2010-12-22

Start date

2008-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Paroxysmal Positional Vertigo. Otitis externa, Postprocedural disorders of ear and mastoid process, not elsewhere classified, Benign paroxysmal vertigo

Interventions

Intervention 1: Dimenhydrinate, 50 mg, TDS, for 2 weeks. Intervention 2: Placebo, TDS, for 2 weeks.

Treatment - Drugs

Dimenhydrinate, 50 mg, TDS, for 2 weeks

Placebo, TDS, for 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: individuals with posterior canal BPPV, confirmed with Dix_Hallpike positional test with classical signs of vertigo and nystagmus Exclusion criteria: lateral or superior semicircular canal involvement, CNS abnormality, bilateral posterior semicircular canal involvement, physical disability, history of vestibular suppressant usage, other labyrinthine diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Recovery of vertigo. Timepoint: daily. Method of measurement: history, Hallpike test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPoopak Izadi

Shahid Mostafa Khomeini hospital, Shahed University

popakizadi@yahoo.com+98 21 8896 9437

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026